Madrigal Pharmaceuticals (NASDAQ:MDGL) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility and Risk

Madrigal Pharmaceuticals has a beta of -1.07, meaning that its stock price is 207% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Valuation & Earnings

This table compares Madrigal Pharmaceuticals and Shuttle Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40 million	11.86	-$288.28 million	($12.80)	-38.50
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($4.77)	-0.10

Shuttle Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Madrigal Pharmaceuticals and Shuttle Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	3	13	1	2.78
Shuttle Pharmaceuticals	1	0	0	0	1.00

Madrigal Pharmaceuticals currently has a consensus price target of $687.00, suggesting a potential upside of 39.40%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Madrigal Pharmaceuticals is more favorable than Shuttle Pharmaceuticals.

Insider and Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Madrigal Pharmaceuticals beats Shuttle Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.